通讯作者: 幸世峰, xinjiang1313@163.com

DOI：10.12201/bmr.202610.00031

Research value of SII and SIRI in prognostic assessment of patients with chronic heart failure complicated by renal dysfunction

• 摘要：【摘要】慢性心力衰竭（chronic heart failure，CHF）合并肾功能不全患者因尿毒素蓄积、氧化应激及内皮损伤，免疫炎症负荷持续升高，预后差于单纯心衰人群。全身免疫炎症指数（systemic immune-inflammation index，SII）与全身炎症反应指数（systemic inflammation response index，SIRI）由血常规复合计算，成本低、可重复检测。现有研究显示，二者升高与全因死亡、心血管死亡、心力衰竭再住院、血栓事件及肾功能恶化相关，在沙库巴曲缬沙坦、钠-葡萄糖共转运蛋白2抑制剂治疗背景下可为治疗反应判读提供补充信息。但SII、SIRI特异性不足，易受感染、贫血、营养状态干扰；各研究阈值与统计方法不统一；且多为单中心、回顾性设计，缺乏外部验证。目前宜将其作为与NT-proBNP、估算肾小球滤过率联合使用的风险提示与补充评估指标，确切价值尚需多中心、前瞻性研究验证。

  关键词： 慢性心力衰竭合并肾功能不全；SII；SIRI；炎症标志物; ; ; 

   

  Abstract: Abstract：Patients with chronic heart failure (CHF) complicated by renal dysfunction exhibit persistently elevated immune-inflammatory burden due to uremic toxin accumulation, oxidative stress, and endothelial injury, and their prognosis is worse than that of patients with heart failure alone. The systemic immune-inflammation index (SII) and the systemic inflammation response index (SIRI), derived from routine blood counts, are low-cost and reproducible. Current evidence indicates that elevated SII and SIRI are associated with all-cause death, cardiovascular death, heart failure rehospitalization, thrombotic events, and worsening renal function, and may provide supplementary information for the interpretation of treatment response in the context of sacubitril/valsartan and sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy. However, SII and SIRI lack specificity, as they are susceptible to infection, anemia, and nutritional status; cutoffs and statistical methods vary across studies; and most existing studies are single-center, retrospective designs lacking external validation. At present, they should be regarded as risk-stratification and supplementary assessment tools used in combination with NT-proBNP and estimated glomerular filtration rate, and their exact value requires verification in multicenter, prospective studies.

  Key words: chronic heart failure complicated by renal dysfunction; systemic immune-inflammation index; systemic inflammation response index; inflammatory biomarker

  提交时间：2026-10-14

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 马家慧, 王忠. 心力衰竭患者血浆C1q/肿瘤坏死因子相关蛋白6、系统性炎症反应指数水平及临床意义. 2025. doi: 10.12201/bmr.202501.00060

  周航宇, 李杰. 射血分数保留的心力衰竭合并慢性肾脏疾病的研究进展. 2025. doi: 10.12201/bmr.202504.00077

  孙延, 贺鑫, 陈芳, 周小淇, 成杰, 唐启群, 成晓华, 郭宗海, 周然. 全身免疫炎症指数联合rSIG 休克指数对老年ICH患者预后的预测价值. 2025. doi: 10.12201/bmr.202509.00020

  张轶予, 费丹婷. 系统性免疫炎症指数结合IL-4、IL-8预测颅脑创伤继发急性肺损伤的临床研究. 2026. doi: 10.12201/bmr.202609.00014

  王敏旭, 帕尔哈提·吐尔逊. 炎症与铁缺乏在心力衰竭患者预后中的预测作用. 2025. doi: 10.12201/bmr.202507.00038

  丁瑢, 李劲榆△, 潘佳茵, 吴梦瑶, 王娓娓, 郑鑫. 射血分数保留型心力衰竭中炎症的作用机制和研究进展. 2026. doi: 10.12201/bmr.202603.00045

  郑杰媚, 邱小芩, 韦吉思, 丘欣雨, 刘娜, 陈思帆. 慢性心力衰竭患者症状群的范围综述. 2025. doi: 10.12201/bmr.202501.00046

  薛琴丹. 健康素养在慢性心力衰竭患者症状负担与疾病不确定感间的调节效应分析. 2024. doi: 10.12201/bmr.202407.00062

  吴晗, 廖才刚, 杨冯静. 温潜法分期治疗慢性心力衰竭探析. 2025. doi: 10.12201/bmr.202510.00061

  彭智平. 基于“肝主脱”理论探讨来复汤治疗元气亏虚型慢性心力衰竭的效果. 2026. doi: 10.12201/bmr.202603.00085

• 序号	提交日期	编号	操作
  1	2026-07-19	10.12201/bmr.202610.00031V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论